Results 221 to 230 of about 84,026 (244)

Open-label placebo hypoalgesia: what works for whom under which circumstances

Pain, 2023
openaire   +2 more sources

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2017
Robert L Coleman, Amit M Oza, Domenica Lorusso   +2 more
exaly  

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Lancet, The, 2008
Robert J Motzer, Thomas E Hutson, Camillio Porta   +2 more
exaly  

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Lancet, The, 2015
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Lancet, The, 2016
Nicola Fazio, Simron Singh, Edward Wolin
exaly  

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Lancet, The, 2017
Andrew Blauvelt, Marjolein de Bruin-Weller, Melinda Gooderham   +2 more
exaly  

Open-Label Placebo in Children With Abdominal Pain or IBS

AAP Grand Rounds, 2022
openaire   +1 more source

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Lancet, The, 2014
Edward B Garon, Oscar Arrieta, Keunchil Park   +2 more
exaly  

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial

Lancet, The, 2016
Neal L Benowitz, Robert J West, A Eden Evins   +2 more
exaly  

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Lancet, The, 2015
Christopher E M Griffiths, Kristian Reich, Mark G Lebwohl   +2 more
exaly